CVS Health Co. (NYSE:CVS) Shares Sold by Westhampton Capital LLC

Westhampton Capital LLC decreased its position in CVS Health Co. (NYSE:CVS) by 12.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,330 shares of the pharmacy operator’s stock after selling 600 shares during the period. Westhampton Capital LLC’s holdings in CVS Health were worth $345,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of CVS Health by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 117,696,285 shares of the pharmacy operator’s stock valued at $9,293,299,000 after purchasing an additional 533,659 shares during the last quarter. Capital World Investors increased its stake in shares of CVS Health by 0.3% in the fourth quarter. Capital World Investors now owns 40,544,702 shares of the pharmacy operator’s stock worth $3,201,410,000 after purchasing an additional 119,631 shares during the period. Capital International Investors boosted its holdings in CVS Health by 47.4% in the 4th quarter. Capital International Investors now owns 33,691,698 shares of the pharmacy operator’s stock valued at $2,660,298,000 after purchasing an additional 10,837,801 shares during the period. Royal Bank of Canada lifted its position in shares of CVS Health by 2.2% in the 3rd quarter. Royal Bank of Canada now owns 14,136,920 shares of the pharmacy operator’s stock worth $987,041,000 after acquiring an additional 303,512 shares during the period. Finally, Norges Bank bought a new position in CVS Health in the fourth quarter worth $1,092,040,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at CVS Health

In related news, Director Edward J. Ludwig bought 1,000 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was acquired at an average cost of $53.88 per share, with a total value of $53,880.00. Following the purchase, the director now directly owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.24% of the company’s stock.

CVS Health Stock Down 0.9 %

NYSE CVS traded down $0.52 on Tuesday, reaching $57.63. 3,359,046 shares of the stock traded hands, compared to its average volume of 12,004,623. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. The company has a market cap of $72.35 billion, a price-to-earnings ratio of 10.22, a PEG ratio of 0.56 and a beta of 0.52. The company has a fifty day moving average price of $59.56 and a 200-day moving average price of $70.13. CVS Health Co. has a 12 month low of $52.77 and a 12 month high of $83.25.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by ($0.38). The company had revenue of $88.44 billion for the quarter, compared to analyst estimates of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The business’s revenue was up 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.20 EPS. As a group, research analysts forecast that CVS Health Co. will post 7.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CVS. Cantor Fitzgerald reiterated a “neutral” rating and issued a $58.00 price objective on shares of CVS Health in a research report on Wednesday, June 12th. Piper Sandler increased their price target on CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Mizuho reduced their target price on CVS Health from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. UBS Group downgraded shares of CVS Health from a “buy” rating to a “neutral” rating and cut their price objective for the company from $85.00 to $60.00 in a report on Thursday, May 2nd. Finally, Wells Fargo & Company reduced their price target on shares of CVS Health from $76.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 7th. Eleven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $75.05.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.